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Abstract
Inherited cardiomyopathy (CM) represents a diverse group of cardiac muscle diseases that present with a broad spectrum of
symptoms ranging from benign to highly malignant. Contributing to this genetic complexity and clinical heterogeneity is
the emergence of a cohort of patients that are double or compound heterozygotes who have inherited two different CM
mutant alleles in the same or different sarcomeric gene. These patients typically have early disease onset with worse clinical
outcomes. Little experimental attention has been directed towards elucidating the physiologic basis of double CM
mutations at the cellular-molecular level. Here, dual gene transfer to isolated adult rat cardiac myocytes was used to
determine the primary effects of co-expressing two different CM-linked mutant proteins on intact cardiac myocyte
contractile physiology. Dual expression of two CM mutants, that alone moderately increase myofilament activation,
tropomyosin mutant A63V and cardiac troponin mutant R146G, were shown to additively slow myocyte relaxation beyond
either mutant studied in isolation. These results were qualitatively similar to a combination of moderate and strong
activating CM mutant alleles aTmA63V and cTnI R193H, which approached a functional threshold. Interestingly, a
combination of a CM myofilament deactivating mutant, troponin C G159D, together with an activating mutant, cTnIR193H,
produced a hybrid phenotype that blunted the strong activating phenotype of cTnIR193H alone. This is evidence of
neutralizing effects of activating/deactivating mutant alleles in combination. Taken together, this combinatorial mutant
allele functional analysis lends molecular insight into disease severity and forms the foundation for a predictive model to
deconstruct the myriad of possible CM double mutations in presenting patients.
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Introduction
Inherited cardiomyopathies (CM) are the most prevalent genetic
disorders of the cardiovascular system [1]. They typically have an
autosomal dominant mode of inheritance and comprise a
spectrum of clinically heterogeneous phenotypes [1]. Cardiomy-
opathies have been categorized into three clinical subtypes,
hypertrophic (HCM), dilated (DCM) and restrictive (RCM)
cardiomyopathy, based on both morphologic and functional
criteria [2,3]. Given the complexity of this disease, inherited
cardiomyopathy is now broadly defined by poor myocardial
performance including diastolic dysfunction, a high risk for sudden
cardiac death and histopathology [3]. Despite the varied natural
histories of the inherited CM subtypes, the genetic basis of these
diseases converge on one subcellular structure, the cardiac
sarcomere [4]. The sarcomere is the primary functional unit of
cardiac muscle that is responsible for contraction and force
generation. Hundreds of mutations in eleven different sarcomeric
genes have co-segregated with a cardiomyopathy phenotype [5].
In genotyped patients, the CM prognosis and penetrance can be
highly variable between identified mutations in the same or
different gene as well as within kindreds [6,7].
Some of the genetic complexity associated with CM can be
attributedtoenvironmental factors and geneticmodifiers.However,
emerging complexity in the form of multiple CM allele inheritance
is also evident [8–14]. Due to the high prevalence of CM alleles
[5,13] it is not surprising that individuals with compound
heterozygous (different CM mutate alleles within the same gene)
or double heterozygous (CM mutations in two different alleles)
genotypes have been documented and likely this population
contributes to the overall clinical heterogeneity [9]. Approximately,
5% of CM patients are double heterozygous [9], and b-myosin
heavy chain (b-MHC) and myosin binding protein-C (MyBP-C) are
generally the affected genetic loci in these individuals [8,10–18].
These loci logically predominate as the highest percentage of CM
cases have single mutations in these two genes [10,17]. There are,
however, documented cases of compound homozygous cardiac
troponin T (cTnT) patients [18–20] as well as double heterozygous
patients with mutations in MyBP-C + cardiac troponin T (cTnT),
MyBP-C + tropomyosin (aTm), MyBP-C + cardiac troponin I
(cTnI), and b-MHC + cTnT [9,11–15,17,20,21]. Disease in these
kindreds tends to be more severe, with CM rapidly progressing to
greater left ventricular hypertrophy, loss of cardiac function, and
increased incidence of sudden cardiac death [9–12,14–18].
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dosage of CM mutant protein is causal for the increased disease
severity [9]. This hypothesis finds support from both animal and in
vitro gene-dosage experiments [9,22–25]. Homozygous and double
heterozygous transgenic mouse models of HCM have recapitulat-
ed increased disease severity and loss of cardiac function similar to
phenotypes observed in humans [12,18,23,24,26–28]. While these
data are supportive of the dose-response hypothesis, the molecular
underpinnings of this heightened disease severity on myocyte
function remain largely unanswered. In addition, protein dosage
has not yet been determined in compound allele CM patients
lending some uncertainty to this dosage hypothesis in humans.
An alternative hypothesis explored here is that multiple CM
mutant proteins cause allele-specific combinatorial primary effects
that uniquely alter sarcomeric function and are not necessarily
linked directly to total mutant gene dosage. Thus, our working
hypothesis is that altered biophysical properties of double mutant
sarcomeric proteins could interact to either heighten or mitigate
the functional cellular outcomes of either mutant allele when
studied in isolation. A prediction of this model is that individuals
inheriting two mutant CM alleles with opposing biophysical
properties may paradoxically have a less severe outcome than
either parent with only a single CM mutant allele. Adding to the
complexity of CM is the realization there are ,467 CM-linked
mutant alleles that have been reported in eleven different
sarcomeric genes [5]. Excluding homozygous genotypes this
translates to 102,000 possible compound/double mutant allele
combinations ([(467
2)2467)/2]), with ,75,000 (102,000-com-
pound heterozygous combinations) of those totaling the number
of double heterozygous genotypes. The total number of compound
heterozygous combinations was derived by the following formula:
((X
2)2X)/2, where X is the number of mutations identified for a
given sarcomeric gene. This formula is calculated for total number
of mutations within each sarcomeric loci and then summated to
equal 33,737 possible genotypes.
In light of the staggering number of potential compound/
double genotypes, an examination of every possible double mutant
combination is unfeasible. We reasoned that a predictive model,
predicated on experimental data, could be implemented as an
index of functional outcomes in multiple CM allele inheritance.
To facilitate this undertaking we assumed that specific CM
mutants could be categorized as Ca
2+ activating (thin filament
activator) or Ca
2+deactivating (thin filament deactivator) arche-
types. Results derived from these archetypes could then inform a
predictive model for extrapolation to all possible CM mutant
combinations. The study employed CM mutant thin filament
regulatory proteins as a proof-of-concept methodology to address
this problem for three reasons. First, this family of sarcomeric
proteins is highly amenable to acute genetic engineering and
structure-function studies [22,29–34]. Second, there is a wealth of
previous data on effects of single thin filament CM mutations on
cardiac myocyte physiology [29,35–37]. Third, while this data is
focused on CM mutations in the thin filament regulatory system,
nearly all CM mutants including the more prevalent thick filament
mutants impact myofilament activation, either positively or
negatively, to directly alter myofilament Ca
2+ sensitivity and thin
filament cooperativity thereby modifying myocyte force develop-
ment and relaxation performance [38–41]. Thick filament
proteins myosin and MyBP-C also affect myocyte function via
established reciprocal interactions between myosin cross-bridge
cycling and thin filament activation [42]. Thus, myosin and
MyBP-C CM mutants converge to affect the activation properties
of the thin filament and can be analyzed by this activation
paradigm. Given the central role of thin filament regulation on
myocyte performance and the realization that both thin and thick
filament CM mutant proteins directly alter myofilament activation
[39,42–44], we reasoned that representative thin filament CM
mutants could serve as surrogates for the breadth of thin and thick
filament CM mutant alleles.
To derive a working model predicting the physiologic effects of
multiple CM alleles, experiments combined CM alleles that
separately cause mild, moderate or strong myofilament activation
(Figure 1A). A combination of a myofilament activator together
with a myofilament deactivator was also tested in separate
experiments. Findings show that two CM mutant myofilament
activator alleles together have additive effects to further activate
the myofilament, and manifest functionally as worsened relaxation
performance. Activator alleles also show evidence of threshold
effects on cellular performance suggesting there exists saturation
points for myofilament dysregulation. The combination of an
activating CM mutant with a deactivating CM mutant caused a
hybrid phenotype that neutralized the primary defects caused by
these CM mutants in isolation. Together these data provide the
basis for a predictive model offering new insight into the functional
ramifications of multiple CM mutant allele inheritance.
Methods
Generation of Recombinant Adenovirus
Adenoviral construction of AdGFP, AdLacZ, aTmE180G,
aTmK70T, aTmA63V, cTnIR146G, and cTnIR193H were
previously described [22,31,45]. All cTnI constructs were derived
from the full-length rodent sequence and tagged with C-terminal
Flag epitope (DYKDDDDK, Sigma) to distinguish the recombi-
nant from the native cTnI; while, the Tm mutants were
engineered into the full-length human Tm [22,31,45]. Stratagene
Quik Change site directed mutagenesis kit was used to engineer
the G159D into full-length human cTnC. All mutants were
confirmed by sequencing. G159D cTnC was subcloned into the
pDC315 AdMax shuttle vector (Microbix Biosystems Inc.) with
and without an HA (Hemagglutinin) epitope tag as previously
described [22]. For all functional studies wild type (WT) represents
the control group which consisted of combined data from non-
transduced, AdcTnIwildtype, and AdcTnIFlag, as we have shown
previously that the expression of the thin filament proteins with
and without a flag tag are functionally innocuous [22,31,45]. Viral
particle lysates were prepared for infection of a cell factory and
plaque assays were used for determining the viral titer in plaque
forming units/ml (pfu/ml) as previously described. The average
titer for viral stocks ranged from 10
10–10
12 pfu/ml.
Adult Rat Cardiac Myocyte Isolation and Dual Adenoviral
Gene Transfer
Rat hearts were excised from heparinized (1500 U/kg) and
anesthetized (Nembutal; 150 U/kg) adult female Sprague Dawley
rats (200 g, Harlan, Indianapolis, IN). Ventricular cardiac
myocytes were isolated via collagenase-hyaluronidase digestion
as previously described [33]. The average yield from rat myocyte
isolations is 1.8610
6 cells with 77% viability. The care and use of
the laboratory animals for this study was in agreement with the
guidelines set forth by the Internal Review Board of the University
of Michigan Committee on the Use and Care of Animals.
Veterinary care was provided by the University of Michigan Unit
for Laboratory Animal Medicine.
Post digestion the myocytes were resuspended in DMEM
(Dulbecco’s Minimum Eagle Media) plus 5% fetal bovine serum
(FBS) and approximately 20,000 cells were plated on laminin-
coated coverslips and incubated for 2 hours. At which time the
Effects of Double HCM Alleles
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myocytes are transduced with recombinant adenoviral vectors.
For single gene transfer myocytes were transduced with an
experimentally predetermine optimal multiplicity of infection
(MOI, range from 20–500) based on the stoichiometric replace-
ment for each vector and level of efficiency. For dual gene transfer
two different recombinant adenoviruses were combined so that the
total MOI was 500 and then simultaneously applied to the plated
myocytes [46].
Protein Expression and Western Blot Analysis
To assess the mutant cTnIs expression and incorporation into
the sarcomere, cultured ventricular myocytes were scraped into
Laemmli sample buffer and prepared for gel electrophoresis by
boiling and sonication. As previously described, cardiac proteins
were separated on a 4–20% gradient SDS-page gel (Criterion, Bio
Rad) and prepared for Western blot analysis. A cTnI specific
polyclonal antibody (AB1927, 1:1000, Chemicon) and Tm specific
monoclonal antibody (Tm-311, Sigma, 1:10
6) were used for
Figure 1. Thin filament regulatory protein targets and efficiency of dual gene transfer. (A) Schematic representation of the troponin
subunits, troponin I (TnI), troponin T (TnT), and troponin C (TnC) and tropomyosin (Tm) the location of CM-linked mutations (gray circles) with in the
secondary structure of troponin and tropomyosin. (B) Representative images (10X) of cultured adult rat cardiac myocytes co-transduced with the
eGFP (200 MOI) and Lac Z genes (200 MOI) 3 days post gene transfer. Bottom panel is a 40X image of one myocyte expressing both eGFP and b-
galactosidase. (C) Summary of the ratio of transduced to total myocytes in a field. Approximately 98% of myocytes are expressing both eGFP and b-
galactosidase by day four in cultured myocytes co-transduced with adenovirus containing the eGFP and Lac Z genes. Data is presented as
mean+SEM, n=5 preparations.
doi:10.1371/journal.pone.0009140.g001
Effects of Double HCM Alleles
PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9140immunodetection. In some instances horseradish peroxidase-
conjugated goat anti-mouse or goat anti-rabbit secondary
antibodies were used for chemilumenescence detection (1:2000,
Amersham) [45,47], while other assays used fluorophore conju-
gated goat anti-rabbit and goat anti-mouse secondary antibodies
(1:5000, Molecular Probes, Invitrogen) for detection by Odyssey
(Licor Biosciences).
Unloaded Dynamic Sarcomere Contractility and Ca
2+
Transients
Sarcomere length measurements and Ca
2+ transients were
measured simultaneously using the Ionoptix system (Ionoptix Co.)
as previously described. A coverslip containing cultured myocytes
was bathed in HEPES buffered medium 199 (M199, 1.8 mM
[Ca
2+]) kept at 37uC. Myocytes were electrically paced at 40 volts
with a frequency of 0.2 Hz. Ca
2+ transient measurements were
accomplished using the excitable Ca
2+ indicator [22,46], Fura-2
AM (Molecular Probes, Invitrogen). Cultured cardiac myocytes
were loaded with 5 mM Fura-2 for 5 minutes followed by a 15
minute deesterification period as previously described [22,46].
Functional measurements were made on myocytes (5–15 per
preparation) obtained from a minimum of 3 preparations.
Results
Efficiency and Targeted Stoichiometric Replacement
from Thin Filament Dual Gene Transfer
To validate the experimental design of dual mutant CM gene
transfer, we determined the efficiency of adenoviral-based dual
gene transfer using reporter genes (Figure 1). Acutely isolated adult
rat cardiac myocytes were simultaneously transduced with two
reporter viral vectors AdeGFP and AdLacZ. Efficiency of
transduction was tracked across time in primary culture.
Figure 1B displays representative images of myocytes after dual
gene transfer, demonstrating the high transduction efficiency of
this approach. After dual gene transfer, 98% of myocytes co-
expressed eGFP and b-galactosidase (Figure 1C) comparable to
previous reports of adenoviral mediated dual gene transfer [48].
Dual gene transfer transduction efficiency was not different when
compared to the efficiency of transduction with a single reporter
gene construct (Figure 1C) [49]. These data show that dual gene
transfer is as rapid and highly efficient as previous reports of single
adenoviral transduction [22,31,34,45].
Dual Expression of CM Mutant Myofilament Activators
We tested three different CM mutant alleles shown previously
and confirmed here to cause weak, moderate, or strong
myofilament activation when tested individually (Table 1). The
primary functional effects of these CM mutants, when expressed
together at the working myocyte level, are presently unknown. We
first tested the functional effects of co-expressing a moderate
myofilament activator, aTmA63V, with a weak activator,
cTnIR146G. Unloaded sarcomere shortening in intact adult rat
cardiac myocytes at physiologic temperatures (37uC) was exam-
ined four days after dual adenoviral gene transfer. A representative
Western blot in Figure 2A demonstrates the targeted stoichiomet-
ric replacement of aTm and cTnI achieved with dual gene transfer
of TmA63V and cTnI R146G. In this pairing, A63V has 1567%
replacement of native aTm, and cTnIR146G achieves approxi-
mately 2065% replacement of native cTnI. This level of
replacement is less than previous reports of single gene transfer
with these particular mutants [31,32,45]. Representative raw
sarcomere shortening traces normalized to peak shortening
amplitude illustrate the pronounced slowing of relaxation
Table 1. Myocyte shortening and Ca
2+ transient parameters.
Sarcomere length (SL) shortening measurements from single intact cardiac myocytes
Baseline SL (mm) Amplitude (nm) Dep vel (%) 50% RTP (ms) 75% RTP (ms) 90% RTP (ms)
WT (n=63) 1.8160.01 149613 17619 0 651 5 2 673 3 4 627
R193H cTnI (n=64) 1.7160.01*
,# 172611* 20611 9 8 615*
,# 355627*
,# 646642*
,#
A63V Tm (n=29) 1.8060.01
+ 189622 16621 4 1 614*
,+ 246622*
,+ 464643*
,+
A63V+R193H (n=29) 1.7160.02*
,# 166616 18612 5 0 627*
,+,# 493660*
,+,# 802677*
,+,#
G159D cTnC (n=36) 1.8560.01*
,+ 166614 20617 2 641
+ 13169
+ 283624
+,#
G159D+R193H (n=36) 1.7560.02*
,+,# 175614 21611 4 0 68*
,+,# 280616*
,+,# 557633*
,+,#
Calcium transient measurements from single intact cardiac myocytes
Baseline (360/380) Amplitude (%BL) D vel Ca
2+ (%) 50% DTP (ms) 75% DTP (ms) 90% DTP (ms)
WT (n=43) 0.8060.01 18.161.6 82632 0 4 615 345627 532636
R193H cTnI (n=44) 0.7960.01 21.861.5
# 79612 285613* 460624* 729642*
A63V Tm (n=19) 0.7860.01 27.962.5*
,+ 77672 7 8 614* 464625*
,+ 757647*
A63V+R193H (n=29) 0.6760.01* 14.562.2
+,# 75693 6 2 622*
,+,# 639641*
,+,# 1,090670*
,+,#
G159D cTnC (n=19) 0.7960.02 14.362.2
+ 74681 9 5 615
+ 343625
+ 551634
+
G159D+R193H (n=26) 0.8860.02 16.061.9 86642 6 8 610*
,# 430617*
,# 656630
+
Wild type (WT) is the control group and consists of combined data from non-transduced, AdcTnI (WT), and AdcTnIFlag. A t-test indicated these data were not
significantly different (P.0.32). Mechanical and Ca
2+ transient data from each experimental and control group were collected simultaneous, thus the WT data
represents the control group for each pairing. 1X4-way ANOVA was used to statistically compare dual gene transfer pairings to single gene transfer and control groups.
Values are represented as the mean 6 SEM and Newman-Keuls post hoc comparisons defined as follows: (*) different from WT, (+) different from R193H cTnI, (#)
different from A63V Tm or G159D cTnC, P,0.05, n=19–64 myocytes derived from 5 different rat heart isolations. Shortening velocity is normalized to the peak
shortening amplitude (Amp). Relaxation time is calculated from peak shortening to 50, 75, or 90% of relaxation. Key: BL= baseline, Dep Vel = sarcomere length
shortening velocity, RTP = relaxation time from peak, D Vel Ca
2+ = rate of rise of the Ca
2+ transient, and DTP = Ca
2+ transient decay time from peak.
doi:10.1371/journal.pone.0009140.t001
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myocytes (Figure 2B). Dual gene transfer of these mutants
(TmA63V + cTnIR146G) had an additive effect when compared
to either mutant alone in which 75% relaxation time was
significantly slowed by 30% (Figure 2C).
The following set of experiments tested the combination of a
strong myofilament activator, cTnIR193H, with a moderate
activator, TmA63V, on myocyte function. Figure 3A is a
representative Western blot probed with anti-Tm and anti-cTnI
antibodies showing the targeted stoichiometric replacement of
cTnIR193H, TmA63V, and A63V+R193H (dual gene transfer
group) relative to WT myocytes (Figure 3A) three days after gene
transfer. With single gene transfer, TmA63V achieved 1865%
replacement and cTnIR193H achieved 5863%, and with dual
gene transfer the replacement of both mutant proteins was reduced
by 6–8% (Figure 3A). In unloaded functional assays representative
sarcomere shortening transients illustrate the effects of aTmA63V,
cTnIR193H, and A63V+R193H on cardiac myocyte relaxation
(Figure 3B). In this assay direct comparisons of myocyte shortening
demonstrated that R193H myocytes are slower to relax than A63V
mutants at 50, 75, and 90% relaxation times (Table 1). Dual gene
transfer of TmA63V and cTnIR193H produced an additive
slowing of relaxation time that was 40% greater than that of
R193H alone (Figure 3C). Ca
2+ transients were simultaneously
measured yielding results similar to mechanical relaxation (Table 1,
Figure 3D). Single gene transfer of A63V and R193H slowed Ca
2+
transient decay time to similar extents, relative to WT myocytes
(Figure 4C, Table 1); whereas, co-expression of TmA63V and
cTnIR193H slowed Ca
2+ transient decay by 39% relative to
cTnIR193H alone (Figure 3C, Table 1). These data show that
within the context of the physiologically intact unloaded myocyte,
the dual incorporation of two myofilament activators from different
sarcomeric loci directly and additively increase the magnitude of
cellular diastolic dysfunction beyond the phenotype of the strongest
activatingallelewithinthepairing.A comparisonof resultsobtained
from the moderate and weak activator pairing (A63V+R146G)
versus the moderate and strong activator pairing (A63V+R193H)
also underscores the relationship between the nature of the
activators (weak, moderate, or strong) and the resulting degree of
diastolic dysfunction, which worsens in combinations with stronger
activating alleles like the A63V+R193H.
Given the role of gene dosage as a critical factor in determining
diseased phenotypes both in vivo [8–10,15,22,35,38] and in vitro
[22,50,51] it is possible that the additive outcomes in this pairing
are due to the global increase in mutant sarcomeric protein
incorporation. While a gene dosage hypothesis was not directly
tested in this study, we propose that the basis for additive outcomes
in A63V+R193H mutant myocytes cannot be entirely accounted
for by an increased amount of total mutant gene dosage, as the
total amount of mutant incorporation was ,60% for both
A63V+R193H and R193H alone (Figure 3A). Despite similar
amounts of CM mutant filaments incorporating into the
sarcomere, the A63V+R193H pairing still additively slowed
relaxation beyond that of R193H cTnI.
As recently shown, the incorporation of cTnIR193H into the
intact sarcomere acutely remodels cardiac myocytes to shortened
resting sarcomere lengths independent of diastolic [Ca
2+] [22].
TmA63V had no effects on resting sarcomere lengths or diastolic
Figure 2. Intact single myocyte shortening from double activating mutations in aTm and cTnI. (A) Representative Western blot showing
non-transduced (WT), R146G cTnI, and A63V Tm + R146G cTnI myocytes. Blots were probed with anti-Tm and anti-cTnI antibodies. (B) Sarcomere
shortening transients from WT, A63V Tm, R146G cTnI, and A63V+R146G transduced myocytes. Traces were normalized to peak shortening to
emphasize the mutant dependent slowing of relaxation. (C) Summary of 75% sarcomere relaxation time. Relaxation time was determined by
calculating the difference from the time of peak shortening to 75% relaxation. Values are represented as the mean+SEM and Newman-Keuls post hoc
comparisons defined as follows: (*) different from WT, (+) different from R146G cTnI, (#) different from A63V Tm, P,0.05, myocytes were derived
from a minimum of 5 different rat heart isolations with n=45 WT, n=40 R146G, and n=40 A63V+R146G myocytes.
doi:10.1371/journal.pone.0009140.g002
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2+ (Figure 3E and F). Myocytes with A63V+R193H had a
phenotype similar to R193H myocytes, as A63V+R193H
myocytes also transitioned to short resting sarcomere lengths
independent of elevated diastolic Ca
2+ (Figure 3E and F). This
suggests that cTnIR193H has a dominant effect over TmA63V to
shortening resting sarcomere lengths in intact cardiac myocytes.
Additional contractile parameters, including sarcomere shortening
amplitude, were not different between groups (Table 1). A63V
mutant myocytes, however, had a significant increase in Ca
2+
transient amplitude relative to WT and dual gene transfer groups
(Table 1). When TmA63V was coexpressed with cTnIR193H,
Ca
2+ transient amplitude was not different from WT myocytes
(Table 1) highlighting the unpredicted combinatorial effects of two
mutant thin filament proteins on Ca
2+ cycling.
Figure 3. Intact single myocyte shortening and Ca
2+ transients from double activating aTm and RCM cTnI mutants. (A) Representative
Western blot from myocytes transduced with R193H cTnI, A63V Tm, or both R193H cTnI and A63V Tm. Non-transduced myocytes served as controls.
Blots were probed with anti-Tm, anti-cTnI antibodies and anti-TnC was used as a loading control (not shown). (B) Representative sarcomere
shortening transients from A63V Tm (HCM), R193H cTnI (RCM), and A63V+R193H transduced myocytes. Traces were normalized to peak shortening to
emphasize the mutant dependent slowing of relaxation. (C) Summary of 75% sarcomere relaxation time and (D)C a
2+ transient decay time. Relaxation
and decay times were determined by calculating the difference from the time of peak shortening/fluorescence to 75% relaxation/decay. (E) Summary
of baseline sarcomere lengths and (F) resting Ca
2+ for all of the experimental groups. Values are represented as the mean + SEM, and Newman-Keuls
post hoc comparisons defined as follows: (*) different from WT, (+) different from R193H cTnI, (#) different from A63V Tm or G159D cTnC, P,0.05,
myocytes were derived from a minimum of 5 different rat heart isolations with n=63/43 WT, n=64/44 R193H, n=29/19 A63V,and n=29/29
A63V+R193H myocytes used for shortening/Ca
2+ cycling experiments.
doi:10.1371/journal.pone.0009140.g003
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2+ transients from a deactivating cTnC and activating cTnI mutant combination.
(A) Representative Western blot from myocytes transduced with R193H cTnI, G159D cTnC, or both R193H cTnI and G159D cTnC. Non-transduced
myocytes served as controls. Blots were probed with anti-cTnI (top panel) and anti-cTnC (bottom panel) antibodies and anti-Tm was used as a
loading control. (B) Representative sarcomere shortening transients from G159D cTnC, R193H cTnI, and G159D cTnC + R193H cTnI transduced
myocytes. Traces were normalized to peak shortening to emphasize the mutant dependent slowing of relaxation. (C) Summary of 75% sarcomere
relaxation time and (D)C a
2+ transient decay time. Relaxation and decay times were determined by calculating the difference from the time of peak
shortening/fluorescence to 75% relaxation/decay. (E) Summary of baseline sarcomere lengths and (F) resting Ca
2+ for all of the experimental groups.
Values are represented as the mean + SEM, and Newman-Keuls post hoc comparsions defined as follows: (*) different from WT, (+) different from
R193H cTnI, (#) different from G159D cTnC, P,0.05, myocytes were derived from a minimum of 5 different rat heart isolations with n=63/43 WT,
n=64/44 R193H, n=36/19 G159D,and n=36/26 G159D+R193H myocytes used for shortening/Ca
2+ cycling experiments.
doi:10.1371/journal.pone.0009140.g004
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CM sarcomeric proteins can directly cause thin filament
deactivation [52–55]. It is therefore possible that individuals could
inherit one CM mutant myofilament activator allele and one CM
mutant deactivator allele. The functional outcomes of such a
pairing have not been addressed in any model system to our
knowledge. Thus, co-transduction of intact adult cardiac myocytes
with CM myofilament deactivator cTnCG159D together with
myofilament activator cTnIR193H was examined. Figure 4A is a
representative Western blot probed with anti-Tm, anti-cTnI, and
anti-cTnC antibodies showing the targeted stoichiometric replace-
ment of native cTnI with R193H cTnI. R193H cTnI replacement
reached 5865% with single gene transfer and was slightly reduced
to 5062% when co-expressed with cTnCG159D (Figure 5A, top
panel). The separation between native cTnC and HA-tagged
cTnCG159D was resolved on an 18% SDS-page gel as shown in
the bottom panel of Figure 5A. G159D cTnC replacement
reached 6064% with single gene transfer and was slightly reduced
to 5062% when co-expressed with cTnIR193H. Representative
sarcomere shortening traces (Figure 4B) demonstrate the 2.5 fold
difference in myocyte relaxation between cTnCG159D and
cTnIR193H mutant myocytes. R193H cTnI significantly slowed
relaxation relative to cTnCG159D and myocytes expressing native
cTnC/cTnI (Figure 4C and Table 1). Dual gene transfer of
cTnCG159D and cTnIR193H resulted in a hybrid phenotype
(Figure 4C), in which the 75% relaxation time was 21% faster in
G159D+R193H myocytes relative to R193H myocytes
(Figure 4C); however, the G159D+R193H myocytes were still
slower to relax when compared to cTnCG159D alone and WT
myocytes (Figure 4C). The decay time of the Ca
2+ transient was
also decreased in G159D+R193H myocyte (Figure 4D), but this
change was not statistically different from cTnIR193H myocyte
Ca
2+ decay times.
The cTnIR193H mutant alone exhibited a characteristic Ca
2+-
independent transition to shortened resting sarcomere lengths
(Figure 4E and F) [22]. The cTnCG159D CM mutant alone had
the opposite effect such that resting sarcomere lengths were
significantly longer than both WT and R193H myocytes, in
addition to having elevated resting diastolic Ca
2+ (Figure 4E and
F). Baseline sarcomere lengths in G159D+R193H myocytes were
significantly longer than those measured in R193H myocytes, but
still significantly shorter than both WT and G159D. The partial
correction of R193H-dependent short resting sarcomere lengths
by cTnCG159D provides further evidence that these mutants can
combine to blunt prominent phenotypic characteristics of a given
CM mutant allele. The strong activator cTnIR193H still exerted a
dominant effect over the deactivator cTnCG159D to slow
relaxation and shorten resting sarcomere length. Collectively,
these data demonstrate that within the context of the physiolog-
ically intact unloaded myocyte coexpressing a deactivating and an
activating sarcomeric allele from different loci partially mitigates
the primary effects elicited by each mutant alone.
Discussion
These results demonstrate that double cardiomyopathy mu-
tants, with mild to strong myofilament activating properties
combine to worsen cellular diastolic dysfunction. These additive
effects on mechanical performance (slowed relaxation and Ca
2+
decay) show evidence of a functional ceiling for some mutant
combinations suggesting there are limits to mechanical dysfunction
induced by compound mutations. We also studied in combination
CM mutants with distinct activating and deactivating properties. A
priori, such combination could result in a dominant effect or,
alternatively, a hybrid functional outcome. Findings here show
that combining CM mutants with opposing effects on myofilament
function (activator + deactivator) produces a hybrid outcome and
evidence of functional neutralization at the intact myocyte level.
This finding raises the possibility that two CM mutant alleles, that
in isolation markedly alter cell performance to cause CM, could in
combination yield near normal cellular physiology. These data are
used to develop a working model (detailed below) for predicting
molecular outcomes on the .100,000 possible CM double mutant
combinations.
Double Activating Alleles: Evidence for Additive and
Functional Threshold Effects
The cause and effect relationship for CM patients with multiple
disease alleles is poorly understood due to a myriad of
compounding factors including environment, genetic modifiers,
increased mutant allele dosage, or allele-specific functional
interactions that likely contribute to the severity of the disease
presentation [4,9,56,57]. Here, two different combinations of
double activating alleles were studied: weak + moderate
(TmA63V+ cTnIR146G) and a moderate + strong (TmA63V+
cTnIR193H). Combinatorial analysis showed additive effects to
further slow relaxation and Ca
2+ transient decay beyond either
mutant studied in isolation. This worsening of cellular diastolic
dysfunction provides a biophysical basis for the increased disease
severity in case reports of double heterozygous CM patients. The
additive slowing of mechanical relaxation in double mutant
myocytes underscores the contribution of both diseased alleles to
the cellular phenotype especially as the total amount of mutant
incorporation was similar between the double mutants when
compared to single mutant myocytes (Figure 3A). It is well known
that myocyte contraction, and by association overall organ
physiology, is highly dependent on the thin filament regulatory
proteins functioning together as a cooperative unit [39]. In the
three-state model of thin filament regulation two activating ligands
Ca
2+ and strong cross-bridge attachment cause the regulatory
proteins to dynamically transition between blocked, closed and
open positions thereby orchestrating the cyclical bouts of diastole
and systole in the beating heart. The transitions between these
regulatory states are initiated by Ca
2+ binding to TnC, which
switches TnI from an inhibitory to a permissive position thereby
permitting Tm movement and access for strong force generating
cross-bridges. The ability of these CM activating alleles to
combine properties is at least in part due to the distinct and vital
roles described above that each gene product (cTnI, cTnC, and
Tm) plays in thin filament regulation.
In this study we ascribe the worsening of myocyte mechanical
performance to the combined effects that gain of function
mutations in cTnI and Tm have on enhancing Ca
2+-mediated
thin filament activation [22,38,40,58]. Individual mutations in
cTnI’s C-teminus (e.g. R146G and R193H) alter TnI switch
function which in turn heightens myofilament Ca
2+ sensitivity and
thus sarcomere relaxation [59,60]. Whereas, gain of function
mutations in Tm increase Tm flexibility lowering the energy
required for Tm movement and making the thin filament more
readily activated [31,61]. Coexpressing these activating mutant
alleles in cardiac myocytes coupled their altered biophysical
properties to further heighten activation at even lower Ca
2+
concentrations when compared to their single mutant counter-
parts. This heightened activation manifests itself as a more severe
cellular diastolic dysfunction, as the sarcomere remains contracted
with decaying Ca
2+ concentrations. While the A63V+R193H
double activator combination slowed relaxation beyond that of
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PLoS ONE | www.plosone.org 8 February 2010 | Volume 5 | Issue 2 | e9140Figure 5. Model of dual gene transfer incorporation of mutant Tm + cTnI and cTnC + cTnI combinations. (A) Native cTnI and aTm is
shown in white. This model predicts that mutant Tm (green) has ordered incorporation starting at the pointed end and moving towards the Z-line,
while the simultaneous transduction of mutant cTnI (red) will stochastically incorporate along the thin filament. As such double mutant regulatory
units containing both mutant Tm and cTnI are located at the pointed end of the thin filament in this dual gene transfer approach. (B) Schematic
depicting the predicted population of regulatory units that decorate the thin filament in this model system and in CM patients. Four populations of
regulatory units consisting of wild type (WT), mutant cTnI alone, mutant Tm alone, and both mutant cTnI and TM (double mutant) are predicted to
constitute the thin filament regulatory system as a whole. The relative proportion of units will be directly related to the percent replacement of native
Tm and cTnI that in a patient will reach an even and random distribution overtime as the thin filaments turn-over. In our model system, TmA63V +
cTnIR193H myocytes very few double mutant regulatory units are predicted as R193H mutant cTnI will be randomly distributed while only 10%
should contain A63V Tm. (C) Native cTnI and cTnC are shown in white. This model predicts that like mutant cTnI (red), mutant cTnC (yellow) will have
stochastic incorporation. Regulatory units containing both mutant cTnC and cTnI are randomly decorated along the entire length of the thin filament.
The incorporation of mutant cTnC is predicted to follow cTnI. (D) Schematic depicting the predicted population of regulatory units that decorate the
thin filament with this dual gene transfer approach. Four populations consisting of wild type (WT), mutant cTnI alone, mutant cTnC alone, and both
mutant cTnI and cTnC (double mutant) regulatory units are predicted to constitute the thin filament regulatory system in our model and in CM
patients. If mutant cTnC follows cTnI then the population of single mutant regulatory units should approach zero with double mutant and WT
regulatory units being more prominent and in a 50:50 distribution. The relative proportion of double mutant regulatory units is predicted to be
directly related to the percent replacement of native cTnC and cTnI.
doi:10.1371/journal.pone.0009140.g005
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additive on a one to one basis as the sum total of relaxation times
for single R193H and A63V myocytes (355+246=601 ms, 75%
Relaxation) was ,17% greater than those measured in
A63V+R193H dual gene transfer myocytes (493 ms). This
suggests that the A63V+R193H combination may reach a
functional threshold or a physiologic limit in which additional
mutant incorporation no longer alters thin filament activation
similar to previous reports where extracting only a fraction of
troponin complexes (as little as 5%) results in nearly maximal Ca
2+
independent thin filament activation [62]. These results support
the prominent role of long range and nearest neighbor interactions
by Tn and Tm and a possible saturation point at which further
thin filament modification would not alter Ca
2+ activation beyond
this saturation point. The functional threshold attained by the
A63V+R193H myocytes in this case could be ascribed to the lower
gene dosage of both mutants attained in the dual gene transfer
model. Perhaps with increased A63V Tm incorporation the
alterations in diastolic dysfunction could be precisely additive.
Alternatively, A63V mutant Tm and R193H mutant cTnI may
overlap in terms of their biophysical roles in thin filament
regulation and thus only combine to fractionally worsen diastolic
dysfunction leaving open the question of possible compound CM
mutant combinations that may encroach on a physiologic limit
where the thin filament attains complete Ca
2+-independent dis-
inhibition and maximal tension generation during relaxation
conditions. The R193H cTnI mutant alone encroaches on this
limit as it has a dominant effect in all combinations to cause a Ca
2+
independent diastolic tone [22,30].
An equally important factor that likely impacts the additive
effects of two activating mutant alleles is the combined
incorporation of each mutant into the sarcomere given the central
role thin filament stoichiometry and cooperativity plays in the
regulation of contraction [40]. The thin filament regulatory system
is comprised of 24 multiplexed regulatory units that span the 1 um
length of actin with a single regulatory unit (Tm, cTnC, cTnT,
and cTnI) for every 7 actin monomers [40]. Each regulatory unit is
coupled by Tm permitting neighboring and long range interac-
tions between other regulatory units [40,63–65]. Studies have
shown that Tm incorporates from the pointed end to the Z-line of
the sarcomere, while cTnI incorporation is stochastic and
uniformly distributed along actin [47]. The differential modes of
incorporation have implications for the double mutants studied
here and for double heterozygous patients. The percentage of CM
mutant protein expression in patients is still unknown but expected
at around 50% per mutant allele from different genetic loci. Given
the estimated total of CM mutant allele expression and the modes
of thin filament incorporation, we postulate that double hetero-
zygous genotypes produce a mixed population of regulatory units
(Figure 5A) in which a proportion of them are WT (unaffected),
mutant cTnI only, mutant Tm only, and mutant cTnI+Tm mixed
regulatory units (Figure 5B). Over a patient’s lifetime the
myofilaments will continually turn-over as the half-life of thin
filament proteins is 3–5.5 days [47,66]. As a result the location of
these mixed regulatory units along the thin filament will constantly
change likely yielding an even and random distribution of mixed,
single mutant, and WT regulatory units in a CM heart despite the
ordered incorporation of Tm in an acute setting. At present the
effects of double mutant regulatory units alone on regulatory
function remains unknown. In our A63V+R193H experiment, the
low percentage of TmA63V incorporation demonstrates that the
change in myocyte physiology is attributed to very few double
mutant regulatory units in tandem with single mutant regulatory
units (Figure 5A and B) as only a small percentage of regulatory
units contain mutant Tm. Despite this small number, the additive
outcomes suggests that nearest neighbor and long range
cooperative interactions between single mutant regulatory units
are more responsible for the enhanced activation in the
A63V+R193H pairing.
Neutralization Effects of Combined Activating and
Deactivating Alleles
A critical insight garnered from this study is that two CM
mutant alleles in combination may not necessarily result in a more
severe cellular dysfunction. This is evident from the deactivator +
activator combination (cTnIR193H + cTnCG159D) in which the
diastolic dysfunction characteristic of single cTnIR193H mutant
was neutralized in part by cTnCG159D producing an interme-
diate activating phenotype. The G159D mutation appears to play
a structural role in the troponin complex, but also interacts with
cTnI’s N-terminus [41,54,67,68]. Chimeric studies showed that
cTnI’s N-terminus influences myofilament Ca
2+ sensitivity [69];
therefore, cTnC G159D may effect hastening of relaxation
through this interaction with the N-terminus of cTnI. In this
case, the complimentary but opposing biophysical properties of
cTnC G159D and cTnI R193H appear to counteract each other.
Thus, at the organ level co-expressing an activating and
deactivating mutant allele could produce a less severe phenotype
than either allele acting alone.
In contrast to the mutant Tm and cTnI pairings, the
modification of the thin filament with cTnCG159D and
cTnIR193H is modeled with a different distribution pattern and
higher percentage of double mutant regulatory units (Figure 5C
and D). It is currently unknown if cTnC has ordered or stochastic
incorporation into the sarcomere. Because sub-cellular pools of
new cTnC have not been discovered [66], cTnC is predicted to
stochastically incorporate into the sarcomere similar to cTnI but
with a delayed time course due to the longer half-life of cTnC (5
days versus 3 days, [47,66]). In this study there was 50%
incorporation of cTnCG159D and cTnIR193H indicating that in
mutant cTnC and cTnI combinations at least half of the
regulatory units should contain a mutant cTnC or cTnI
(Figure 5C and D). By chance alone there is a higher probability
that both mutants will incorporate into the same regulatory unit
than the number predicted for Tm + cTnI pairings (Figure 5A) in
this model system. If cTnC incorporation follows the cTnI pattern
then the affected regulatory units (,1/2) should contain both
mutant proteins (Figure 5C and D) with the rest of the regulatory
units being WT. In a double heterozygous CM patient with
mutant troponin subunits, the distribution of the mixed regulatory
units should achieve a random and even distribution across the
thin filament similar to the equilibrium achieved with Tm+TnI
combinations. If cTnC follows cTnI replacement patients with this
mutant allele combination are predicted to have a 50:50
distribution of double mutant and WT regulatory units. In this
case the mutant regulatory units exert a dominant effect over WT.
Predictive Model for Compound CM Mutants
Using experimental data from activating and deactivating
sarcomeric CM mutants obtained here and elsewhere as
foundations, a working model was developed to promote
predictive insights into myocyte function of the theoretically
possible tens of thousands of compound CM combinations. The
model was constructed by categorizing single mutant CM alleles
by their functional properties as myofilament activators or
deactivators, and by the strength with which these properties
have been altered. The activation properties of numerous single
sarcomeric mutants in both the thick and thin filament have
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sarcomeric can be incorporated into the model as they all
fundamentally effect myofilament regulation [8,29,36,37,70–73].
The model employs vector addition to illustrate the merging of the
primary functional effects of each distinct mutant allele in a given
double heterozygous combination. Here a linear vector represents
a single mutant allele (Figure 6). The length of the vector reflects
the individual strength of activation/deactivation (weak, moderate,
or strong; Figure 6), and the direction of the vector represents the
activation properties of a mutant (right arrow = activator, left
arrow = deactivation; Figure 6A and B). The single mutant
vectors of a double heterozygous combination are then added
head to tail. Two vectors (alleles) in the same direction are
summated to give the net outcome. If the net direction points
towards activation results in more severe diastolic dysfunction as
represented by the blue positive sloping gradient (Figure 6A). By
contrast, summated myofilament deactivators are predicted to
hasten relaxation and alter contractility [52,55,74] as represented
by the red negative sloping gradient (Figure 6A). Support for this
model comes from the data presented here in which a weak/strong
and a moderate/strong activator combination both additively
worsened diastolic function. This model is further supported by
the heightened pathology and increased mortality reported in a
CM double heterozygous mouse model that expresses both strong
(R403Q Myosin) and moderate activator (G203S cTnI) alleles
[28]. The model incorporates functional ceiling effects obtained by
combining two strong activator alleles (or two strong deactivating
alleles) where the myofilament activation (or deactivaiton) reaches
a functional threshold and is no longer additive on a one to one
basis.
This model also incorporates the neutralizing effects of activator
and deactivator alleles in combination (Figure 6C). Here, the
deactivator and the activator are combined to predict the
outcome. The degree of neutralization in activator/deactivator
combinations is represented by the trapezoid in which the
spectrum of colors (red to purple to blue) depicts the addition of
two opposing activating alleles of different strengths. Support for
neutralizing effects comes directly from activator/deactivator
alleles in combination (Figure 6), as well as from a mouse model
coexpressing a CM-linked activating and deactivating Tm [75].
Further support for this model comes from a recent study
demonstrating that the expression of moderate and mild
Figure 6. Working model of additive and neutralizing outcomes for double heterozygous genotypes based on the combine effects
of allele-specific thin filament activation. In the models depicted in all panels the arrows represent the individual allele as a linear vector. The
length of the arrow represent the magnitude of activation/deactivation of the thin filament caused by the mutant allele alone, which is classified as
weak, moderate, or strong. The arrow’s direction represents the allele’s alteration of thin filament activation in which a rightward pointing arrow
(positive direction) represents activation and a leftward pointing (negative direction) arrow represents deactivation. (A) Double Activating Allele
Model: the positive sloping gradient represents the additive slowing of relaxation and heightened severity of diastolic dysfunction that occurs with
the combination of two activating mutant alleles from different sarcomeric loci. The combination of two activating alleles is represented by adding
two activating allele vectors together, which yields a higher degree of activation and thus more severe diastolic dysfunction. Some double activating
allele combinations may cause the thin filament to become saturated thereby approaching a threshold of activation in which the combination of two
vectors is not additive on a one to one basis. (B) Double Deactivating Allele Model: the negative sloping gradient represents the predicted additive
consequence to accelerate relaxation and reduce contractility that occurs with the combination of two deactivating mutant alleles from different
sarcomeric loci. The combination of two deactivating alleles is represented by adding two activating allele vectors together but in the negative
direction, which yields a higher degree of deactivation and thus altered contractility with enhanced relaxation. Some double deactivating allele
combinations may also result in saturation thereby approaching a threshold of deactivation. (C) Mixed Model of Activating + Deactivating Alleles: the
combination of two alleles with different activation properties is depicted by the addition of a positive gradient and vector (activating allele) anda
negative gradient and vector (deactivating allele). This combination results in mitigating effects, in which the primary phenotypes of each individual
mutant are neutralized (represented by the trapezoid) when the opposing alleles are co-expressed.
doi:10.1371/journal.pone.0009140.g006
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myocyte contractility [52]. An important outcome of the
experimental results and model is that offspring inheriting two
malignant CM alleles, that separately cause myofilament activa-
tion in one parent and deactivation in the other, could combine to
produce a functional neutralization and benign presentation.
For experimental purposes we did not employ the more
prevalent double heterozygous genotypes, which predominantly
consist of MyHC and MyBP-C mutant allele combinations. As
myosin is a vital ligand required for maximal activation of tension
development [42,44], b-MHC mutant alleles can be classified
within this activator/deactivator paradigm and thus are well suited
for our working model. The R403Q MHC can be considered a
moderate-strong activating allele [8,71–73], and based on our
model, the functional outcome of having an R403Q b-MHC allele
paired with another activator would be predicted to cause an
additive worsening of diastolic dysfunction (Figure 6). While this
activating activating/deactivating paradigm should be tested on
other mutant sarcomeric alleles, support for our model can be
derived from double heterozygous patients with a combined
myosin and troponin mutation that have early morbidity and an
increased incidence of surgical treatment and sudden cardiac
death, as well as the increased mortality in the MyHC R403Q +
G203S cTnI double heterozygous mice described above [76].
In conclusion, our findings show at the cellular/molecular level
double mutant thin filament proteins have direct and combina-
torial effects to alter cellular diastolic function. The mechanistic
basis for additive/mitigating effects cannot be solely due to total
mutant gene dosage alone, but also appears to be highly
dependent on the population and location of double mutant
regulatory units along the thin filament and the biophysical
properties of the effected sarcomeric protein in terms of the
activating/deactivating nature and the strength of these mutant
alleles. These results also underscore that the primary outcome for
double heterozygous patients may not necessarily cause a
worsening of the disease phenotype particularly in cases where
the genotype produces an activating and a deactivating mutant
myofilament protein.
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